Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMJD2C shRNA is a short hairpin RNA (shRNA) designed to target and knock down the expression of the histone demethylase JMJD2C (also known as KDM4C). JMJD2C acts as a coactivator for hypoxia-inducible factor 1 (HIF-1) and is involved in breast cancer progression by demethylating histone H3 at lysine 9 (H3K9), which enhances HIF-1 binding to hypoxia response elements (HREs). This transcriptional activation upregulates genes required for metabolic reprogramming (such as BNIP3, LDHA, PDK1, and SLC2A1) and lung metastasis (such as LOXL2 and L1CAM). Knockdown of JMJD2C using shRNA has been shown to inhibit breast tumor growth and spontaneous lung metastasis in preclinical mouse models, highlighting its potential as a therapeutic target in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JMJD2C shRNA.